Eylea Injection, Solution
Product Images NDC 61755-005

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Eylea (NDC 61755-005). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Regeneron Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Eylea 01)

An instructional line drawing showing hands holding a vial with a rubber stopper. One hand is pressing down on the stopper, demonstrating how to access the vial's contents. The image likely relates to preparation or handling of an intravitreal injection solution.*

FDA Label Image

Figure 2 (Eylea 02)

An instructional line drawing showing hands removing the cap from a vial. The illustration is related to the preparation or administration of an injectable solution, such as EYLEA (aflibercept) injection.*

FDA Label Image

Figure 3 (Eylea 03)

An instructional line drawing illustrating how to remove the cap from a syringe. The image shows two hands holding the syringe and pulling off the cap, indicated by arrows.*

FDA Label Image

Figure 4 (Eylea 04)

An instructional line drawing showing a syringe being filled from a vial. One hand holds the vial upside down, and the other hand pulls back the syringe plunger to draw liquid from the vial into the syringe.*

FDA Label Image

Figure 5a (Eylea 05)

An instructional illustration showing two hands preparing an intravitreal injection syringe. One hand holds the syringe barrel, while the other removes the cap from the needle. The image includes an arrow indicating the direction for removing the needle cap, suggesting a step in medication administration or preparation.*

FDA Label Image

Figure 5b (Eylea 06)

An instructional black and white line drawing showing hands preparing an intravitreal injection. One hand holds a syringe filled with liquid, while the other hand is positioned near the syringe, likely demonstrating the preparation or administration technique.*

FDA Label Image

Figure 6 (Eylea 07)

An instructional diagram showing a syringe with a solution inside. The syringe is marked with volume graduations, and a black arrow points to just above the 0.1 mL mark, highlighting the drawn solution level in the syringe barrel.*

FDA Label Image

Figure 7 (Eylea 08)

This figure contains two line graphs labeled VIEW 1 and VIEW 2, depicting mean change in visual acuity (measured in letters) over weeks up to 96. The graphs compare EYLEA 2mg dosed every 8 weeks, EYLEA 2mg dosed every 4 weeks, and Ranibizumab 0.5mg dosed every 4 weeks, showing trends in improvement at multiple time points.*

FDA Label Image

Figure 8 (Eylea 09)

Two line graphs titled COPERNICUS and GALILEO show the mean change in visual acuity (letters) over 24 weeks. Both depict EYLEA 2 mg administered every 4 weeks versus a control group. The graphs illustrate visual acuity improvements with EYLEA increasing up to around +17 to +18 letters, while control groups show minimal or negative changes.*

FDA Label Image

Figure 9a (Eylea 10)

A line graph titled 'VIBRANT' showing mean change in visual acuity (letters) over 24 weeks. It compares two groups: EYLEA 2 mg administered every 4 weeks (represented by triangles) and a control group (represented by circles). The EYLEA group shows a greater increase in visual acuity than the control group over time.*

FDA Label Image

Figure 9b (Eylea 11)

Two line graphs depicting mean change in visual acuity (letters) over 100 weeks from the VIVID and VISTA clinical trials. Both graphs compare EYLEA 2 mg given every 8 weeks, EYLEA 2 mg every 4 weeks, and a control group, showing visual acuity improvement trends in labeled groups over time.*

FDA Label Image

Figure 10 (Eylea 12)

The image shows a carton label for EYLEA (aflibercept) Injection for Intravitreal Injection by Regeneron Pharmaceuticals, Inc. It specifies 2 mg/0.05 mL strength in a single-use vial. The label includes packaging details, including the inclusion of a 3-mL vial, needles, and a syringe, along with regulatory information and barcodes.*

FDA Label Image

Figure 11 (Eylea 13)

EYLEA (aflibercept) Injection 2 mg/0.05 mL single-dose pre-filled syringe carton label. The label states it is for intravitreal injection and contains one sterile, single-dose pre-filled glass syringe with solution. The labeler is Regeneron Pharmaceuticals, Inc. The packaging design includes product name, dosage, NDC code 61755-005-01, and a syringe illustration.*

FDA Label Image

Figure 12a And B (Eylea 14)

An instructional figure showing the dosing line for a 0.05 mL volume for EYLEA (aflibercept) injection. Figure 12a displays a syringe filled to the 0.05 mL dose line for an adult dose. Figure 12b provides a close-up view emphasizing the dose line after expelling air bubbles and excess drug, noting the flat plunger edge meeting the solution level.*

FDA Label Image

Figure 13a And B (Eylea 15)

Illustrations labeled Figure 13a and Figure 13b showing dose measurement for preterm infants with a syringe. Figure 13a highlights the 0.01 mL dose line on the syringe barrel. Figure 13b shows a close-up of the syringe tip with annotations indicating the dose line, solution after expelling air bubbles and excess drug, and the flat plunger edge.*

FDA Label Image

Figure 14 (Eylea 16)

Two line graphs showing mean change in visual acuity (letters) over 96 weeks for treatments labeled EYLEA 2mg every 8 weeks, EYLEA 2mg every 4 weeks, and Ranibizumab 0.5mg every 4 weeks. The top graph (VIEW 1) and bottom graph (VIEW 2) compare these regimens, with improvements peaking around week 52 and then declining or stabilizing. The variables are mean change in visual acuity on the vertical axis and weeks on the horizontal axis.*

FDA Label Image

Figure 15 (Eylea 17)

Two line graphs titled 'COPERNICUS' and 'GALILEO' showing mean change in visual acuity (letters) over 24 weeks. Both graphs compare EYLEA 2 mg administered every 4 weeks (triangles) versus a control group (circles). EYLEA shows a marked increase in visual acuity, reaching approximately +17 to +18 letters, while the control group shows little to no improvement.*

FDA Label Image

Figure 16 (Eylea 18)

A line graph titled VIBRANT showing the mean change in visual acuity (letters) over 24 weeks. The x-axis represents weeks, ranging from 0 to 24, and the y-axis represents mean change in visual acuity from 0 to 20 letters. Two lines compare EYLEA 2 mg administered every 4 weeks and a control group. The EYLEA group shows a steady increase reaching about +17 letters, while the control group shows a smaller increase reaching about +6.9 letters.*

FDA Label Image

Figure 17 (Eylea 19)

Two line graphs titled 'VIVID' and 'VISTA' depicting the mean change in visual acuity (letters) over 100 weeks. Each graph compares three groups: EYLEA 2 mg every 8 weeks (squares), EYLEA 2 mg every 4 weeks (triangles), and a control group (circles). Both graphs show increases in visual acuity for EYLEA groups, with the control group showing minimal change.*

FDA Label Image

Figure 18 (Eylea 20)

A bar chart comparing the proportion of patients over time in weeks (8, 12, 24, 40, 52) for three groups: Control (sham), EYLEA 2Q16, and EYLEA 2Q8. The vertical axis shows the proportion of patients as a percentage, with values increasing from week 8 to week 52.*

FDA Label Image

Principal Display Panel (2 mg/0.05 mL Vial Carton)

The image shows the packaging label for EYLEA (aflibercept) Injection, 2 mg (0.05 mL of a 40 mg/mL solution), a single-dose vial for intravitreal injection. The carton includes a 3-mL glass vial of EYLEA, an 18-gauge filter needle for vial withdrawal, a 30-gauge needle for injection, a 1-mL plastic syringe, and prescribing information. Labeler is Regeneron Pharmaceuticals, Inc.*

FDA Label Image

Principal Display Panel (2 mg/0.05 mL Syringe Carton)

Packaging label for EYLEA (aflibercept) Injection, a 2 mg (0.05 mL of 40 mg/mL solution) intravitreal injection. The label indicates it is a single-dose pre-filled syringe supplied by Regeneron Pharmaceuticals, Inc. The carton contains one sterile, single-dose pre-filled glass syringe and one Prescribing Information insert. The label features the product name, dosage, and image of the syringe along with regulatory and handling information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.